Osteoporosis and rheumatic diseases
Submitted: 28 July 2014
Accepted: 28 July 2014
Published: 28 June 2014
Accepted: 28 July 2014
Abstract Views: 7440
PDF: 3190
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- W. Grassi, C. Montecucco, Approved indications and other possible utilizations of anti-TNFa biologic drugs , Reumatismo: Vol. 57 No. s4 (2005)
- G. Valesini, M. Cutolo, Effects of TNF antagonists on immune and neuroendocrine system , Reumatismo: Vol. 57 No. s4 (2005)
- A. Furlan, M. Podswiadek, F. Cozzi, S. Todesco, Tenosynovitis of the ankles as onset of sarcoidosis in a patient with ulcerative colitis , Reumatismo: Vol. 57 No. 3 (2005)
- P. Quattrocchi, A. Barrile, D. Bonanno, L. Giannetto, M. Patafi, V. Tigano, B. Ferlazzo, The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases , Reumatismo: Vol. 57 No. 2 (2005)
- F. Salaffi, A. Stancati, Disability and quality of life of patients with rheumatoid arthritis: assessment and perspectives , Reumatismo: Vol. 56 No. s1 (2004)
- L. Riente, The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis , Reumatismo: Vol. 56 No. s1 (2004)
- G. Adami, A. Giollo, M. Rossini, G. Orsolini, C. Benini, O. Viapiana, D. Gatti, A. Fassio, Different fracture risk profile in patients treated with anti-osteoporotic drugs in real-life , Reumatismo: Vol. 72 No. 2 (2020)
You may also start an advanced similarity search for this article.